Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis

M Aapro, B Coiffier, J Dunst, A Osterborg, H U Burger, M Aapro, B Coiffier, J Dunst, A Osterborg, H U Burger

Abstract

To assess the early effect of epoetin beta on survival and tumour progression in anaemic patients with cancer, data were pooled from nine randomised clinical trials comparing epoetin beta with placebo or standard care. Studies were not primarily designed to assess these end points. Follow-up was for treatment duration plus 4 weeks following therapy completion. All adverse events (AEs) were retrospectively reviewed blinded, for progression. Thromboembolic events were also assessed. Data analysis involved standard statistical tests. Overall, 1413 patients were included (epoetin beta, n = 800; control, n = 613; 56% haematological, and 44% solid). Median initial epoetin beta dose was 30,000 IU/week. Overall survival during months 0-6 was similar with epoetin beta and control (0.31 vs 0.32 deaths/patient-year). No increased mortality risk was seen with epoetin beta (relative risk (RR) 0.97, 95% CI: 0.69, 1.36; P = 0.87). There was a significantly reduced risk of rapidly progressive disease for epoetin beta (RR 0.78, 95% CI: 0.62, 0.99; P = 0.042). Epoetin beta was associated with a slightly higher frequency of thromboembolic events vs control (5.9% vs 4.2% of patients) but thromboembolic-related mortality was identical in both groups (1.1%). Epoetin beta provided a slight beneficial effect on tumour progression and did not impact on early survival or thromboembolic-related mortality.

Figures

Figure 1
Figure 1
Kaplan–Meier curves of (A) overall survival and (B) time to progression.
Figure 2
Figure 2
Summary of HRs of (A) overall survival and (B) time to progression.

References

    1. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A (2003) Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162: 1789–1806
    1. Antonadou D, Cardamakis E, Puglisi M (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomized phase III study. Eur J Cancer 37(Suppl 6): A530
    1. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A (2004) Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 3: CD003407
    1. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489–498
    1. Bohlius J, Wilson J, Seidenfeld S, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett C, Langensiepen S, Hyde C, Engert A (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708–714
    1. Boogaerts M, Coiffier B, Kainz C, Epoetin Beta QOL, Working Group (2003) Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88: 988–995
    1. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214–2221
    1. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122: 386–393
    1. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegier L, Essers U, Greil R, Grossi A, Jager G, Le Mevel A, Najman A, Silingardi V, Spriano M, Van Hoof A, Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446–4453
    1. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(Suppl 7): 43–46
    1. Dunst J (2004) Erythropoietin and radiotherapy: a dangerous combination? Strahlenther Onkol 180: 133–135
    1. Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9(Suppl 5): 18–30
    1. Food and Drug Administration (2004) Oncologic Drugs Advisory Committee. Meeting on evolving safety issues associated with erythropoietic products. Briefing information. (4 May 2004)
    1. Glaser CM, Millesi W, Kornek GV, Long S, Schull B, Watzinger F, Selzer E, Lavey RS (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705–715
    1. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amade RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23: 6941–6948
    1. Henke M, Laszig R, Rube C, Schafer U, Hasse KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255–1260
    1. Kettelhack C, Hones C, Messinger D, Schlag PM (1998) Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 85: 63–67
    1. Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107(23 Suppl 1): I17–I21
    1. Leyland-Jones B, Mahmud S (2004) Erythropoietin to treat anaemia in patients with head and neck cancer [letter]. Lancet 363: 80
    1. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandi S, Makhson A, Roth A, Dodwell D, Basalga J, Biakhov M, Valuckas K, Voznui E, Lui X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960–5972
    1. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapaport B, Epoetin Alpha study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874
    1. Mittelman M, Neumann D, Peled A, Kanter P, Haren-Ghera N (2001) Erythropoietin induces tumour regression and antitumour immune responses in murine myeloma models. Proc Natl Acad Sci USA 98: 5181–5186
    1. Möbus VJ, Untch M, Du Bois A, Lueck H-J, Thomssen C, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C (2004) Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (⩾4+LN). First results of an AGO-trial. J Clin Oncol 22: 14S Abstract 513
    1. NeoRecormon® SmPC (2006) Available from: 27 September 2006)
    1. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrman R, Netter-Pinon J, Tubiana-Mathiew N, Zwierzina H (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255–260
    1. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkdyrov K, Hedenus M, Messinger D, Epoetin Beta Hematology Study Group (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486–2494
    1. Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najmen A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma – a randomized multicenter study. Blood 87: 2675–2682
    1. Österborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 129: 206–209
    1. Rau B, Schlag PM, Willeke F, Herforth C, Stephen P, Frake W (1998) Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO). Eur J Cancer 34: 992–998
    1. Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stusche M, Thews O, Vaupel P (2003) Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phy 55: 1358–1362
    1. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, van der Haeven JJ, Reeds NS, Fairlamb DJ, Chan SY, Godfrey KA Kristenson GB, van Tinteren H, Ehmer B (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15: 174–182
    1. Thews O, Kelleher DK, Vaupel P (2001) Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61: 1358–1361
    1. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gatekey J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211–1220
    1. Vaupel P, Mayer A (2004) Erythropoietin to treat anaemia in patients with head and neck cancer [letter]. Lancet 363: 992

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj